Clinical research summary

Synbiotics as a Potential Treatment for IBD – Preclinical Study in a Mouse Model
A preclinical study published in Clinical Nutrition ESPEN (2024) found that the synbiotic preparation Synbio1 significantly improved IBD-like symptoms in mice, outperforming standard treatment in some measures. Effects were more pronounced in females. Synbio1 modulated clinical scores, colon pathology, and plasma biomarkers, supporting its potential as a therapeutic strategy for IBD and warranting further clinical investigation. Read more here

Synbiotic 2000 in Early Enteral Nutrition for Trauma Patients – A Randomized Clinical Trial
A randomized study (JPEN, 2007) on 113 trauma patients found that early enteral nutrition with Synbiotic 2000 significantly reduced infections and intestinal permeability compared to glutamine, fiber, or peptide diets. Conducted at the University Medical Centre in Ljubljana, the study highlights the potential of synbiotics in improving clinical outcomes following severe injury. Synbiotic-treated patients experienced fewer complications, warranting further research into this therapeutic approach.  Read more here

Synbiotic 2000Forte reduced infections, sepsis, and ICU stays in critically ill trauma patients
In this 2006 double-blind RCT, 65 ICU trauma patients receiving Synbiotic 2000Forte had significantly lower infection (63% vs. 90%), sepsis (49% vs. 77%), and mortality rates (14.3% vs. 30%) compared to placebo. They also showed reduced inflammation and spent fewer days on ventilators and in ICU, suggesting clinical benefit in critical care. Read more here

Synbiotic 2000 lowers infection and inflammation in ICU trauma patients
In this 2009 double-blind RCT with 72 ICU patients, Synbiotic 2000 significantly reduced bloodstream infections, CRP, LPS, and white blood cell counts. Only 5.6% developed primary bacteremia vs. 25% on placebo, with mortality halved (13.9% vs. 27.8%). Synbiotic 2000 delayed onset of sepsis and showed strong immunomodulatory effects, supporting its role in reducing infection-related complications in critical care. Read more here

Synbiotic 2000 reduces post-transplant infections in liver recipients
In this 2005 double-blind RCT with 66 liver transplant patients, those receiving Synbiotic 2000 had significantly fewer infections (3% vs. 48%) and required shorter antibiotic therapy than those given fiber only. Despite more non-infectious complications in the synbiotic group, infection rates remained lower, suggesting a synergistic protective effect. Early enteral synbiotic nutrition may effectively prevent postoperative infections in high-risk surgical patients. Read more here

Synbiotic 2000 lowers infections after pancreatic surgery
In this 2007 double-blind RCT of 80 patients undergoing pylorus-preserving pancreatoduodenectomy (PPPD), Synbiotic 2000 reduced bacterial infections to 12.5% versus 40% in the fiber-only group. Synbiotic-treated patients also required shorter antibiotic therapy. Although hospital and ICU stays were not significantly different, these results support the use of early enteral synbiotics to reduce postoperative infections safely and cost-effectively. Read more here

Synbiotic 2000 improves liver function in cirrhotic patients
In this 2007 randomized trial, short-term treatment with Synbiotic 2000 significantly improved liver function in cirrhotic patients, with 44.4% improving in Child-Pugh classification vs. 0% in placebo. Synbiotic use increased beneficial gut bacteria, enhanced ICG clearance, and improved key liver biomarkers. No deterioration occurred in treated patients, suggesting synbiotics may support hepatic recovery through gut flora modulation. Read more here

Synbiotic 2000 reverses minimal hepatic encephalopathy in cirrhosis
In this 2004 randomized trial with 97 cirrhotic patients, 50% of those treated with Synbiotic 2000 showed reversal of minimal hepatic encephalopathy (MHE) vs. 13% with placebo. Synbiotic treatment significantly reduced E. coli, Staphylococcus, and ammonia levels, while increasing beneficial Lactobacillus. Improvements in gut flora, Child-Pugh score, and fecal pH suggest synbiotics as a promising, non-pharmacological alternative to lactulose for managing MHE. Read more here

Synbiotics plus BCAAs improve cognition in hepatic encephalopathy
In this 2019 placebo-controlled pilot study of 61 cirrhotic patients with hepatic encephalopathy (HE), 8 weeks of combined Synbiotic 2000 and BCAA supplementation led to significant cognitive improvements compared to placebo, particularly in executive function tests. Benefits occurred without changes in ammonia levels. This is the first study to suggest that synbiotics plus BCAAs may enhance cognitive outcomes in HE, supporting further investigation. Read more here

Synbiotic 2000 increases gut probiotics in HIV-1 patients
In this 2012 double-blind pilot trial, 38 women with chronic HIV-1 infection received Synbiotic 2000 or a fiber-only placebo for 4 weeks. Synbiotic treatment significantly increased levels of probiotic bacteria in stool, demonstrating effective gut colonization. While no major changes in immune activation or microbial translocation were observed, the findings support further research into synbiotics for improving gut health in HIV patients. Read more here

Synbiotic 2000 may support liver function after hepatectomy
In this 2007–2008 pilot RCT of 33 liver resection patients, Synbiotic 2000 showed a potential benefit in liver function recovery following uncomplicated surgery. While overall liver function was similar between groups, synbiotic-treated patients without complications had better postoperative liver function. No severe side effects occurred. Larger studies are needed to confirm whether synbiotics can aid liver regeneration after major hepatic surgery. Read more here

Synbiotic 2000 prevents lung injury in experimental peritonitis
In this 2007 animal study, rats pretreated for 3 weeks with Synbiotic 2000 showed complete protection against peritonitis-induced acute lung injury, with reduced neutrophil infiltration and lung edema compared to fiber or placebo groups. Probiotic-only treatment also offered protection, while synbiotics had the strongest effect. These findings suggest synbiotics may offer a promising, low-risk strategy to prevent inflammation-related organ damage, warranting further research. Read more here

Subcutaneous probiotics reduce lung injury in sepsis-induced rats
This 2005 animal study found that subcutaneous administration of live Lactobacillus significantly reduced lung inflammation and tissue damage in rats with sepsis-induced injury. Treated groups showed lower PMN infiltration and milder lung pathology compared to controls. These results suggest that non-oral delivery of probiotics may offer immune-modulating benefits in critical care, highlighting a novel therapeutic approach for preventing organ failure in sepsis. Read more here